Atai Life Sciences BV

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company, which engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany.

The company specializes in developing psychedelics as therapies.

Why Shares of atai Life Sciences Climbed 14.58% on Tuesday

NEW YORK and BERLIN, Nov. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor events & healthcare conferences:

atai Life Sciences to Participate in November Investor Events & Healthcare Conferences

NEW YORK and BERLIN, Oct. 25, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropsychiatric diseases and its subsidiary, Perception Neuroscience (“Perception”), today announced the completion of enrollment of its Phase 2a clinical trial to evaluate the safety and efficacy of a single intravenous infusion (IV) dose of PCN-101 (R-ketamine). R-ketamine is a stereoisomer of ketamine being developed for treatment-resistant depression (TRD). TRD patients are partially or entirely unresponsive to antidepressants and face issues of misdiagnosis, prolonged depressive periods, co-occurring mental and physical disorders, and longer periods with a lower quality of life than patients suffering from less severe depression.

atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression

NEW YORK and BERLIN, Oct. 20, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the agenda for its virtual R&D Day. During this event, management and scientific leaders will provide a comprehensive review of atai's diversified mental health pipeline. The event will also provide updates on near-term catalysts, with a focus on the upcoming Phase 2a topline results for PCN-101 (R-ketamine) for treatment-resistant depression (TRD).

atai Life Sciences Announces R&D Day Agenda

– atai has initiated a Phase 1 proof-of-concept clinical trial to demonstrate the safety, tolerability, and direct-to-brain delivery of intranasal INB-01, a sol-gel based drug-delivery technology.

atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology

– Initial results showed that single ascending oral dosing of KUR-101 produces dose-dependent analgesia (pain relief) with effects on respiration comparable to that of placebo.

atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD

ATAI is at a value inflection point, it has slimmed its drug discovery pipeline and promises proof of concept data within two years. ATAI has taken on debt to give it a cash runway through to 2025, by which time it must have generated compelling evidence for its drugs.

Atai Life Sciences: Decentralized Drug Discovery Platform

- atai has dosed the first subject in their Phase 1 single-ascending dose (SAD) trial of VLS-01 with topline results expected in H1 2023.

atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT

NEW YORK and BERLIN, Oct. 04, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in in the following investor events & host a virtual R&D Day in October:

atai Life Sciences to Participate in October Investor Events & Host Virtual R&D Day

COMPASS Pathways

It's risky, and you'll need to wait a while for a payoff, assuming the stars align for there to be one.

Is Now a Good Time to Invest In Psychedelics Stocks?

They haven't experienced any setbacks, but their shares are still down.

Buying These 2 Battered Growth Stocks Right Now Could Be Brilliant

NEW YORK and BERLIN, Sept. 07, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor conferences in September:

atai Life Sciences to Participate in September Investor Events

These two trends on the frontier of medicine could present lucrative opportunities for investment.

2 Top Trends to Invest $2,000 in Ahead of the Crowd

Cybin

Ameri Holdings

GH Research PLC

Mind Medicine MindMed

Advisorshares Psychedelics ETF

Psychedelics stocks are becoming increasingly mainstream, in part due to changing social attitudes. Psychedelic drugs “are a loosely grouped class of drugs that are able to induce altered thoughts and sensory perceptions.

7 Psychedelics Stocks to Buy for a Big Drug Boom

Atai Life Sciences N.V. (NASDAQ:ATAI ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Greg Weaver – Chief Financial Officer Stephen Bardin – Deputy Chief Financial Officer Florian Brand – Chief Executive Officer Srini Rao – Chief Scientific Officer Conference Call Participants Judah Frommer – Credit Suisse Andrew Tsai – Jefferies LLC Greg Weaver Hi, everyone.

Atai Life Sciences N.V.'s (ATAI) CEO Florian Brand on Q2 2022 Results - Earnings Call Transcript

- Added an anticipated additional year of runway into 2025 through securing non-dilutive debt facility from Hercules combined with execution of cost optimizations by prioritizing atai's development programs with anticipated meaningful near-term clinical value inflections - Key achieved R&D milestones include completion of the clinical phase of the Drug-Drug-Interaction (DDI) study of PCN-101, database lock for the GRX-917 Phase 1 trial, completion of SAD portion of ongoing KUR-101 Phase 1 trial, and initiation of VLS-01 Phase 1 trial - Non-dilutive financing facility of up to $175M, plus $312M existing cash on hand as of June 30, 2022, gives atai access to up to $487M to continue developing next generation mental health treatments

atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update

-  Non-dilutive financing facility, plus $312M existing cash on hand as of June 30, 2022, gives atai access to up to $487M to continue developing next generation mental health treatments

atai Life Sciences Secures Term Loan Facility for up to $175 Million from Hercules Capital

NEW YORK and BERLIN, Aug. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, plans to announce its second quarter 2022 financial results and business update on Monday, August 15, 2022.

atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update

Defiance Next Gen Altered Experience ETF

PSYK ETF

Seelos Therapeutics

On July 13, 2022, two amendments passed in the House of Representatives that would provide psychedelic drug treatment to veterans and active duty service members. A documentary based on Michael Pollan's 2018 book, "How to Change Your Mind," is one of Netflix's most-watched shows.

The Growth Potential Of Psychedelics Stocks And ETFs

Compass

There are a couple of proposed regulations and policies in the pipeline.

New Regulations for Psychedelics? Here's What Investors Need to Know

Psychedelic stocks are in focus following new legislation from both the Senate and the House that has bipartisan support. The post Dear Psychedelic Stocks Fans, Watch This Key Catalyst appeared first on InvestorPlace.

Dear Psychedelic Stocks Fans, Watch This Key Catalyst

Butterfly Network

3D Systems

StoneCo

Surface Oncology Inc

Cathie Wood remains bullish on staple ARK names like Tesla and Teladoc. Still, the fund manager has added several new companies to her ETFs.

5 New Cathie Wood Stocks to Watch Right Now

ATAI is backed by Peter Thiel. Its decentralized business model is pretty unique.

Atai Life Sciences: Leading But Early Stage Psychedelic Therapeutics Developer

Farfetch

Twilio

Tech stocks have crashed, but Wall Street should eventually remember why the love affair began in the first place. After the tech crash, it makes sense to invest in a large quantity of names.

Will Tech Stocks Recover? 3 Names To Buy

Dr. Chad Beyer will join as CEO on July 1, 2022 Dr. Chad Beyer will join as CEO on July 1, 2022

News for Atai Life Sciences BV Stock (ATAI)